Clinical Trial Update: A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease [Phase 4]

View source ↗

Summary

Phase 4 trial update investigating the renal safety of Visipaque Injection 320 mgI/mL in patients with chronic kidney disease; study terminated with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Visipaque Injection 320 mgI/mL (iodixanol)

Snippet

Sponsor: GE Healthcare | Conditions: Chronic Kidney Diseases | Phase 4 | Status: TERMINATED | Results posted: 2019-12-17